9.20
-0.23(-2.44%)
Currency In USD
| Previous Close | 9.43 |
| Open | 9.43 |
| Day High | 9.45 |
| Day Low | 9.15 |
| 52-Week High | 13.16 |
| 52-Week Low | 6.19 |
| Volume | 848,572 |
| Average Volume | 1.1M |
| Market Cap | 516.44M |
| PE | -36.8 |
| EPS | -0.25 |
| Moving Average 50 Days | 10.54 |
| Moving Average 200 Days | 8.73 |
| Change | -0.23 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $25.82 as of August 18, 2025 at a share price of $9.2. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $908.37 as of August 18, 2025 at a share price of $9.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 06, 2025 11:30 AM GMT
CELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Z
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
GlobeNewswire Inc.
Aug 04, 2025 11:30 AM GMT
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing th
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
GlobeNewswire Inc.
Jul 28, 2025 10:00 AM GMT
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted